


OVERVIEW

PRESS RELEASES **EVENTS & PRESENTATIONS** CORPORATE GOVERNANCE MANAGEMENT BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT THE BOARD FINANCIAL INFORMATION SEC FILINGS ANNUAL REPORTS QUARTERLY RESULTS STOCK INFORMATION HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE INVESTOR FAQS CONTACT US EMAIL ALERTS



Investor Relations

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use

CONTAGIOUS ideas

To Drive Therapy Compliance

in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

STOCK QUOTE

Price Change High

Jun 15, 2018 9:16 PM EDT

VIEW DETAILS

Copyright Nasdaq. Minimum 15 minutes delayed.

STOCK CHART



PRESS RELEASES

June 13, Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference

May 31, Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20
Presentations at ASM Microbe 2018

May 29,
2018

Melinta Therapeutics Announces Closing of
Underwritten Public Offering and Exercise in
Full of Underwriters' Option to Purchase
Additional Shares of Common Stock

EVENTS & PRESENTATIONS

FILTER RESET

Jun 20, 2018

Melinta Therapeutics, Inc. at the JMP Securities Life Sciences Conference

CLICK HERE FOR WEBCAST

Jun 06, 2018

Melinta Therapeutics, Inc. at the Jefferies 2018 Global Healthcare Conference

CLICK HERE FOR WEBCAST

May 08, 2018

Melinta Therapeutics Q1 2018 Earnings Call

CLICK HERE FOR WEBCAST

Q1 2018 Earnings Presentation 365.4 KB



Melinta Therapeutics, Inc. ©2018 ALL RIGHTS RESERVED | Terms of Use